ANNX Annexon Biosciences
Price Chart
Executive Summary
Annexon Biosciences reported fourth quarter and full year 2025 financial results, highlighting a strong cash position of $238.3 million and progress in its late-stage clinical programs for vonaprument (GA) and tanruprubart (GBS). The company expects topline Phase 3 data for vonaprument in Q4 2026 and plans a U.S. BLA submission for tanruprubart in 2026 based on FORWARD study data.
Key Financial Metrics
Actionable Insight
Investors should monitor upcoming topline data from the Phase 3 ARCHER II trial in Q4 2026, which could be a major value driver. The MAA filing in Europe for tanruprubart represents near-term regulatory risk/reward, while the planned 2026 U.S. BLA submission depends on FORWARD study outcomes.
Key Facts
- Cash, cash equivalents, and short-term investments totaled $238.3 million as of December 31, 2025, providing runway into the second half of 2027.
- R&D expenses increased to $184.7 million in 2025 from $119.4 million in 2024, driven by advancement of the Phase 3 ARCHER II trial and regulatory filings for tanruprubart.
- Net loss attributable to common stockholders was $208.5 million in 2025, up from $138.2 million in 2024.
- Topline Phase 3 ARCHER II data for vonaprument in geographic atrophy (GA) expected in Q4 2026.
- Marketing Authorization Application (MAA) filed in Europe for tanruprubart in Guillain-Barré Syndrome (GBS); U.S. BLA submission anticipated in 2026.
Financial Impact
Increased R&D spending by $65.3 million YoY to $184.7 million; net loss widened to $208.5 million in 2025 from $138.2 million in 2024.
Risk Factors
- Clinical trial results may not meet endpoints, particularly the primary endpoint of visual acuity preservation in the ARCHER II trial.
- Regulatory delays or rejections for tanruprubart in Europe or the U.S. could negatively impact valuation.
- Cash runway extends into H2 2027, but additional financing may be required depending on development timelines and commercialization plans.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264990 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 16, 2026
24d ago
|
ANALYST-UPGRADE
| $5.11 $5.02 | ▼ −1.76% | ▼ −0.93% | $5.12 (+0.20%) |
|
May 12, 2026
28d ago
|
ANALYST-UPGRADE
| $5.44 $4.96 | ▲ +8.82% | ▲ +8.90% | $5.12 (+5.88%) |
|
May 7, 2026
4w ago
|
Press Release
| $5.69 $5.37 | ▼ −5.62% | ▼ −7.09% | $5.12 (−10.02%) |
|
Apr 16, 2026
7w ago
|
ANALYST-UPGRADE
| $6.33 $6.06 | ▼ −4.27% | ▼ −5.25% | $5.12 (−19.12%) |
|
Apr 16, 2026
7w ago
|
ANALYST-UPGRADE
| $6.33 $6.06 | ▼ −4.27% | ▼ −5.25% | $5.12 (−19.12%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $5.54 $6.05 | ▲ +9.21% | ▲ +5.26% | $5.12 (−7.58%) |
|
Mar 2, 2026
14w ago
|
Insider Cluster
| $5.52 $5.59 | ▲ +1.27% | ▲ +2.48% | $5.12 (−7.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access